Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ModernaCHIX:0QFD 67 EV-to-EBIT is -5.75 as of Jul. 27, 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 67/100 and a GF Value™ of €14.50 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 378 Biotechnology companies, Moderna ranks worse than 264550% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Moderna's Enterprise Value is €15,424 Mil.
Moderna's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-2,682 Mil. Therefore, Moderna's EV-to-EBIT for today is -5.75.
The historical rank and industry rank for Moderna's EV-to-EBIT or its related term are showing as below:
CHIX:0QFd'
s EV-to-EBIT Range Over the Past 10 Years
Min: -94.02 Med: -4.59 Max: 139.76
Current: -5.64
During the past 10 years, the highest EV-to-EBIT of Moderna was 139.76. The lowest was -94.02. And the median was -4.59.
CHIX:0QFd's EV-to-EBIT is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 12.775
vs CHIX:0QFd: -5.64
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Moderna's Enterprise Value for the quarter that ended in Mar. 2026 was €9,359 Mil.
Moderna's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,682 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna EV-to-EBIT Related Terms
Moderna EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Moderna's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:0QFD vs BNTX, INSM, INCY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Moderna's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Moderna's EV-to-EBIT falls into.
Moderna's current Enterprise Value is €15,424 Mil.
Moderna's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,682 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (CHIX:0QFD) has a EV-to-EBIT of -5.75 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Moderna and its competitors. According to the industry distribution chart, Moderna ranks #999999 out of 378 companies in the Biotechnology industry.
Is Moderna's EV-to-EBIT too high?
Moderna's current EV-to-EBIT is -5.75. Based on the distribution chart, Moderna ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moderna has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's EV-to-EBIT compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Moderna ranks #999999 out of 378 companies for EV-to-EBIT. This places Moderna in the lower half of its industry. The industry median EV-to-EBIT is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Moderna and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moderna's current EV-to-EBIT is -5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €14.50, compared to a current price of €70.49 — trading 386.1% above its estimated fair value. The current EV-to-EBIT is -5.75. Moderna's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current EV-to-EBIT is -5.75 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (CHIX:0QFD) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of €70.49 is trading 386.1% above its estimated GF Value™ of €14.50.
GuruFocus considers Moderna to be Significantly Overvalued.
Key valuation signals for CHIX:0QFD:
EV-to-EBIT: -5.75
GF Value™: €14.50 vs. price of €70.49 (386.1% above fair value)
No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
67GF Score
Get the complete analysis for CHIX:0QFD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:0QFD has been successfully added to your 
